Lee 2003

1  Treatments

Studied treatment  off-pump CABG

Control treatment  conventional on-pump CABG

Concomittant treatments  -

Age (mean), years  -

female (%)  -

2  Patients

Patients  patients undergoing CABG

Inclusion criteria  -

Exclusion criteria  -

LVEF >50%  -

Diabetes (%)  -

LVEF (mean), %  -

3  Methods

Blinding  open

Design  -

Centers  -

Geographical area  -

Sizes  30/30
4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>graft occlusion of internal thoracic artery</td>
<td>/30</td>
<td>/30</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>atrial fibrillation</td>
<td>/30</td>
<td>/30</td>
<td>7/30</td>
<td>0,58 [0,19; 1,78]</td>
</tr>
<tr>
<td>saphenous vein graft occlusion</td>
<td>/30</td>
<td>/30</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>new cardiac revascularization</td>
<td>/30</td>
<td>/30</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV events</td>
<td>/30</td>
<td>/30</td>
<td>1/30</td>
<td>3,00 [0,12; 76,74]</td>
</tr>
<tr>
<td>death</td>
<td>/30</td>
<td>/30</td>
<td>0/30</td>
<td>0,33 [0,01; 8,53]</td>
</tr>
<tr>
<td>stroke</td>
<td>/30</td>
<td>/30</td>
<td>0/30</td>
<td>1/30</td>
</tr>
</tbody>
</table>

5 References